Developer docs
API playgroundTry for free, no card

Search company profiles

Neurotech International

Full company profile

uuid0006721

Namestring
Neurotech International
Websiteurl
neurotechinternational.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Neurotech International Limited is an Australian clinical-stage biotechnology company listed on the Australian Securities Exchange (ASX: NTI), headquartered in Perth and founded in 2016. The company is developing therapeutic candidates targeting Autism Spectrum Disorder (ASD), a therapeutic area with significant unmet medical need and limited approved treatment options for core ASD symptoms. Its lead candidate appears to be suramin sodium (KZ101), referenced in clinical trial context as the primary asset advancing through development.

The company's business model is presently pre-commercial: it operates in clinical development with no marketed products, no publicly disclosed pricing model, and no commercial distribution infrastructure. Revenue recognition would only become material upon regulatory approval and successful commercialization of its pipeline therapies. Neurotech employs between 11 and 50 staff and is led by CEO Wolfgang Storf, founder and non-executive director Adrian Attard Trevisan, and CCO Mario Raciti. The company's value proposition is the development of a therapeutic pipeline for ASD, an indication where over 25 companies are reportedly pursuing pipeline therapies.

In December 2025, Neurotech requested a trading halt on its listed securities pending a capital raising announcement, indicating active fundraising to advance the clinical pipeline. The company previously raised $4,000,000 in an October 2017 funding round. The provided financial figures (revenue and EBITDA reported in trillions of dollars) are internally inconsistent with a sub-50-employee clinical-stage biotech and should be treated as unreliable input; on the underlying fundamentals, the company is pre-revenue.

Short descriptiontext

Neurotech International is a publicly listed Australian clinical-stage biotechnology company developing therapeutic candidates for Autism Spectrum Disorder (ASD), with lead candidate suramin sodium (KZ101). The Perth-based company is pre-revenue and advancing its ASD pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPerth, Australia
HQ citystring
Perth
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
autism therapeutics development, clinical-stage biotechnology, neurological drug development, central nervous system therapies, medical device manufacturing
Industry2 codes
1Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryYes
2Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Therapeutics — Autism Spectrum Disorder
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neurotech International is a clinical-stage biotechnology/medical device company developing novel therapeutic candidates for central nervous system disorders, with a primary focus on autism spectrum disorder (ASD). Its lead asset is suramin sodium (KZ101), which is being advanced through clinical development as a potential treatment for ASD.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information is available from the provided sources. The company website (neurotechinternational.com) displays only a loading/verification page, and no product details are present in the available news articles.

Product and service1 record
1Suramin sodium (KZ101)
CategoryNeurological Therapeutics — Autism Spectrum Disorder
Description

Suramin sodium (KZ101) is Neurotech International's lead proprietary therapeutic candidate in clinical development, intended to address the significant unmet medical need for pharmacological treatment options for autism spectrum disorder.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Axsome Therapeutics
TypeDirect peer
Description

Clinical CNS-focused biotech developing therapeutics for neurological and psychiatric disorders. Comparable as a small-cap publicly listed CNS biotech that has navigated from clinical development to commercialization, offering a trajectory benchmark for Neurotech.

2Roche
TypeBroad incumbent
Description

Global pharmaceutical leader that has run major ASD clinical programs (e.g., balovaptan) and operates broadly in CNS/neurodevelopmental therapeutics. Comparable as a benchmark for capital intensity, trial design, and competitive positioning in ASD, even though Neurotech operates at a vastly different scale.

3Ovid Therapeutics
TypeDirect peer
Description

Clinical-stage biotech focused on rare neurological and neurodevelopmental conditions, including Angelman syndrome and Fragile X — both adjacent to ASD. Closely comparable in indication strategy, company size, and public-market funding model.

4Yamo Pharmaceuticals
TypeDirect peer
Description

Emerging clinical-stage company developing a first-in-class therapy specifically for the core symptoms of ASD. Directly comparable as an ASD-focused clinical-stage therapeutic developer with similar size and stage profile.

5Zynerba Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biotech developing cannabinoid-based therapeutics for neurodevelopmental and psychiatric conditions including ASD and Fragile X syndrome. Highly comparable in target indication, modality, and small-cap clinical-stage profile.

6MapLight Therapeutics
TypeEmerging player
Description

Clinical-stage neuroscience company developing therapeutics for CNS disorders with partial overlap in neurodevelopmental indications. Comparable as a clinical-stage CNS peer with a similar public/private funding trajectory.

7BioMarin Pharmaceutical
TypeBroad incumbent
Description

Established rare-disease biopharmaceutical company with a CNS and neurodevelopmental franchise (e.g., Voxzogo for rare skeletal conditions; pipeline adjacent to neuro). Useful as a comparator for the orphan/specialty CNS commercial model and valuation framework.

8Sage Therapeutics
TypeDirect peer
Description

Clinical-stage CNS-focused biotech developing therapeutics for neurological and neuropsychiatric conditions. Highly comparable in stage, listing status, and CNS drug development focus, providing a useful reference for valuation, capital strategy, and pipeline prioritization.

9Curemark
TypeDirect peer
Description

Clinical-stage biotech developing CM-AT for autism spectrum disorder, one of the most direct ASD-only therapeutic competitors. Closely comparable on indication focus and clinical-stage development stage.

10Stalicla
TypeEmerging player
Description

Clinical-stage biotech developing precision therapeutics for neurodevelopmental disorders including ASD subgroups. Comparable as a niche ASD-focused clinical developer, useful for benchmarking the precision-medicine angle in ASD drug development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurotech International

Neurological Therapeutics — Autism Spectrum Disorderneurotechinternational.com

Neurotech International is a publicly listed Australian clinical-stage biotechnology company developing therapeutic candidates for Autism Spectrum Disorder (ASD), with lead candidate suramin sodium (KZ101). The Perth-based company is pre-revenue and advancing its ASD pipeline.

What Neurotech International does

Neurotech International Limited is an Australian clinical-stage biotechnology company listed on the Australian Securities Exchange (ASX: NTI), headquartered in Perth and founded in 2016. The company is developing therapeutic candidates targeting Autism Spectrum Disorder (ASD), a therapeutic area with significant unmet medical need and limited approved treatment options for core ASD symptoms. Its lead candidate appears to be suramin sodium (KZ101), referenced in clinical trial context as the primary asset advancing through development.

The company's business model is presently pre-commercial: it operates in clinical development with no marketed products, no publicly disclosed pricing model, and no commercial distribution infrastructure. Revenue recognition would only become material upon regulatory approval and successful commercialization of its pipeline therapies. Neurotech employs between 11 and 50 staff and is led by CEO Wolfgang Storf, founder and non-executive director Adrian Attard Trevisan, and CCO Mario Raciti. The company's value proposition is the development of a therapeutic pipeline for ASD, an indication where over 25 companies are reportedly pursuing pipeline therapies.

In December 2025, Neurotech requested a trading halt on its listed securities pending a capital raising announcement, indicating active fundraising to advance the clinical pipeline. The company previously raised $4,000,000 in an October 2017 funding round. The provided financial figures (revenue and EBITDA reported in trillions of dollars) are internally inconsistent with a sub-50-employee clinical-stage biotech and should be treated as unreliable input; on the underlying fundamentals, the company is pre-revenue.

Neurotech International firmographics

Firmographics
Name
Neurotech International
Website
https://neurotechinternational.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurotech International is a publicly listed Australian clinical-stage biotechnology company developing therapeutic candidates for Autism Spectrum Disorder (ASD), with lead candidate suramin sodium (KZ101). The Perth-based company is pre-revenue and advancing its ASD pipeline.
Ownership category
akta.pro rank

Neurotech International industry classification

Industry
Product category
Neurological Therapeutics — Autism Spectrum Disorder
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
akta.pro secondary industry
Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

  • Autism therapeutics development
  • Clinical-stage biotechnology
  • Neurological drug development
  • Central nervous system therapies
  • Medical device manufacturing

Where Neurotech International is headquartered

Location

Headquarters

HQ city
Perth
HQ country
Australia
HQ region
Oceania

Markets served

Neurotech International business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Neurotech International product offering

Product offering

Core offering

Neurotech International is a clinical-stage biotechnology/medical device company developing novel therapeutic candidates for central nervous system disorders, with a primary focus on autism spectrum disorder (ASD). Its lead asset is suramin sodium (KZ101), which is being advanced through clinical development as a potential treatment for ASD.

Product overview

No product or service information is available from the provided sources. The company website (neurotechinternational.com) displays only a loading/verification page, and no product details are present in the available news articles.

Differentiator

Problem solved

Functional benefit

Products and services

  • Suramin sodium (KZ101) Suramin sodium (KZ101) is Neurotech International's lead proprietary therapeutic candidate in clinical development, intended to address the significant unmet medical need for pharmacological treatment options for autism spectrum disorder.

Companies that use Neurotech International

Customer profile

Segments1 record

Ideal customer profiles1 record

Neurotech International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Neurotech International partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Neurotech International competitors and assessment

Company assessment

Direct peers

  • Axsome Therapeutics: Clinical CNS-focused biotech developing therapeutics for neurological and psychiatric disorders. Comparable as a small-cap publicly listed CNS biotech that has navigated from clinical development to commercialization, offering a trajectory benchmark for Neurotech.
  • Ovid Therapeutics: Clinical-stage biotech focused on rare neurological and neurodevelopmental conditions, including Angelman syndrome and Fragile X — both adjacent to ASD. Closely comparable in indication strategy, company size, and public-market funding model.
  • Yamo Pharmaceuticals: Emerging clinical-stage company developing a first-in-class therapy specifically for the core symptoms of ASD. Directly comparable as an ASD-focused clinical-stage therapeutic developer with similar size and stage profile.
  • Zynerba Pharmaceuticals: Clinical-stage biotech developing cannabinoid-based therapeutics for neurodevelopmental and psychiatric conditions including ASD and Fragile X syndrome. Highly comparable in target indication, modality, and small-cap clinical-stage profile.
  • Sage Therapeutics: Clinical-stage CNS-focused biotech developing therapeutics for neurological and neuropsychiatric conditions. Highly comparable in stage, listing status, and CNS drug development focus, providing a useful reference for valuation, capital strategy, and pipeline prioritization.
  • Curemark: Clinical-stage biotech developing CM-AT for autism spectrum disorder, one of the most direct ASD-only therapeutic competitors. Closely comparable on indication focus and clinical-stage development stage.

Broad incumbents

  • Roche: Global pharmaceutical leader that has run major ASD clinical programs (e.g., balovaptan) and operates broadly in CNS/neurodevelopmental therapeutics. Comparable as a benchmark for capital intensity, trial design, and competitive positioning in ASD, even though Neurotech operates at a vastly different scale.
  • BioMarin Pharmaceutical: Established rare-disease biopharmaceutical company with a CNS and neurodevelopmental franchise (e.g., Voxzogo for rare skeletal conditions; pipeline adjacent to neuro). Useful as a comparator for the orphan/specialty CNS commercial model and valuation framework.

Emerging players

  • MapLight Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS disorders with partial overlap in neurodevelopmental indications. Comparable as a clinical-stage CNS peer with a similar public/private funding trajectory.
  • Stalicla: Clinical-stage biotech developing precision therapeutics for neurodevelopmental disorders including ASD subgroups. Comparable as a niche ASD-focused clinical developer, useful for benchmarking the precision-medicine angle in ASD drug development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Neurotech International social profiles

Digital presence

Neurotech International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurotech International leadership team

Management profile

Number of profiles

Profiles3 records

Neurotech International funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurotech International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurotech International

What does Neurotech International do?

Neurotech International is a clinical-stage biotechnology/medical device company developing novel therapeutic candidates for central nervous system disorders, with a primary focus on autism spectrum disorder (ASD). Its lead asset is suramin sodium (KZ101), which is being advanced through clinical development as a potential treatment for ASD.

When was Neurotech International founded?

Neurotech International was founded in 2016. It employs 11 to 50 people.

Where is Neurotech International based?

Neurotech International is headquartered in Perth, Australia, in the Oceania region.

Who are Neurotech International's main competitors?

Direct peers on record are Axsome Therapeutics, Ovid Therapeutics, Yamo Pharmaceuticals, Zynerba Pharmaceuticals, Sage Therapeutics and Curemark. Broad incumbents are Roche and BioMarin Pharmaceutical. Emerging players are MapLight Therapeutics and Stalicla.

Does Neurotech International have an API?

No public API is recorded for Neurotech International.

What industry is Neurotech International in?

Neurotech International's product category is Neurological Therapeutics — Autism Spectrum Disorder. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KalkineNeurotech International (ASX:NTI): FDA IND Clearance Advances NTI164 Autism ProgramNeurotech International received Investigational New Drug clearance from the US Food and Drug Administration for its autism therapy candidate NTI164, enabling a US pharmacokinetic clinical study. This regulatory milestone allows the company to expand its development pathway into the US market while it continues the Phase 3 Beyond Harmony trial in Australia. The clearance marks progress toward global regulatory submissions but does not constitute approval of the treatment.KalkineMerchant Funds Management Becomes Substantial Holder in Neurotech International with 7.38% StakeMerchant Funds Management Pty Ltd and its associated entities have become substantial holders in Neurotech International Limited, disclosing a combined relevant interest of 118,698,491 shares representing 7.38% voting power as of August 11, 2026. The acquisition was finalized through a Form 603 filing with the ASX on August 13, 2026, detailing various share parcels acquired between September 2024 and August 2026.KalkineNeurotech International (ASX:NTI): FDA Clearance Opens New U.S. Pathway for NTI164 ProgramNeurotech International received FDA clearance for its Investigational New Drug application for NTI164, allowing the company to pursue clinical development in the U.S. alongside its ongoing Phase 3 trial in Australia. NTI164 is a cannabinoid-based treatment targeting autism spectrum disorder and related neurodevelopmental conditions, with potential studies planned to further support its development.KalkineNeurotech International (ASX:NTI) Rises As NTI164 Clears US Regulatory StepNeurotech International received US FDA clearance for an Investigational New Drug application for its drug NTI164, allowing the company to proceed with a paediatric clinical study in the United States. The company also announced a AUD 3.15 million R&D tax incentive loan to support the sustained capital requirements of its clinical programs.TipranksNeurotech Confirms Compliance as New Shares Enter Secondary TradingNeurotech International Ltd has confirmed compliance with continuous disclosure obligations as new fully paid ordinary shares enter secondary trading on the Australian market. The company, which is developing an oral cannabinoid therapy for paediatric neurological disorders, issued these shares without a prospectus under specific provisions of the Australian Corporations Act.KalkineNeurotech International Applies to Quote 293.3 Million Ordinary Shares at $0.014 EachNeurotech International Limited has applied to the Australian Securities Exchange (ASX) for the quotation of 293,328,277 ordinary shares at an issue price of AUD $0.014 each. These securities were issued as part of a placement previously announced on August 4, 2026, bringing the company's total quoted ordinary fully paid securities to approximately 1.62 billion. The filing confirms that no further issues of securities are required to complete this specific transaction.KalkineNeurotech International (ASX:NTI) Raises $4.5 Million to Advance NTI164 Phase III Autism Clinical TrialNeurotech International secured approximately $4.5 million through a share placement to fund the Phase III clinical trial for its autism therapy, NTI164. The capital raising involves the issuance of roughly 321.4 million new shares and is supported by existing and new institutional investors. Proceeds will sustain operations through the expected topline data readout from the double-blind, placebo-controlled study.Kalkine MediaCould Neurotech (ASX:NTI) Lead a Sharper Sector Read?Neurotech is being evaluated in the context of clinical cannabis research as the Australian market shifts focus toward product access, funding, and execution within smaller healthcare companies. The article emphasizes the importance of the company's operating model aligning with current market demands for visibility and cash generation, as the sector undergoes a nuanced assessment rather than a broad enthusiasm. Moving forward, Neurotech's success will depend on demonstrating clear operational evidence amid a changing market landscape.KalkineNeurotech International Completes Share Issuance Under Corporations Act Relief ProvisionsNeurotech International Limited completed the issuance of ordinary fully paid shares under relief provisions of the Australian Corporations Act on July 21, 2026. The company confirmed compliance with regulatory disclosure requirements while noting that its lead therapy, NTI164, has completed Phase II/III trials for Autism Spectrum Disorder with statistically significant results.StockheadNTI (ASX) News & Expert Insights from StockheadNeurotech International Limited is advancing its clinical trials for NTI164, a proprietary cannabis-derived drug formulation, targeting paediatric neurological disorders such as Autism Spectrum Disorder (ASD). The company has completed Phase I/II trials in ASD and commenced Phase II/III randomised, double-blind, placebo-controlled trials in Q4 CY2022. Additionally, Neurotech is conducting further trials for PANDAS/PANS, Rett Syndrome, and Cerebral Palsy during CY2023.